Connor, Clark & Lunn Investment Management (CC&L)
PETX

Connor, Clark & Lunn Investment Management (CC&L)’s Aratana Therapeutics, Inc. PETX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-26,750
Closed -$96K – 1128
2019
Q1 		$96K Buy
+26,750
New +$116K ﹤0.01% 868

Other funds holding PETX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PETX Position: Q2 2019 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 26,750 shares — an estimated $96K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PETX in Q1 2019 and held it in 1 quarter. The position peaked at $96K in Q1 2019. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 26,750 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $96K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Aratana Therapeutics, Inc. in Q1 2019 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Aratana Therapeutics, Inc. position peaked at $96K in Q1 2019.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2019, filed 7 Aug 2019.